Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

US expansion update

6 Jan 2023 07:00

RNS Number : 8680L
Omega Diagnostics Group PLC
06 January 2023
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega", the "Company" or the "Group")

 

US expansion update

 

Maiden US Laboratory FoodPrint® installation,

Appointment of US importer for FoodPrint® and

First PO from US CLIA certified Lab heralds start of US expansion

 

Omega (AIM: ODX), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, announces that it has now received the maiden purchase order ('PO') for its FoodPrint® system from a CLIA certified ('Clinical Laboratory Improvement Amendments') laboratory in the United States, and has appointed a new US importer for FoodPrint® kits.

 

Using a small finger prick of blood, the FoodPrint® test can quickly identify an individual's unique food sensitivity reactions, allowing the patient to adjust and plan to a new diet and address IgG-mediated food sensitivities. FoodPrint® analyses up to 222 foods for IgG antibodies and is trusted by more than 150 laboratories worldwide, to help fast track a guided elimination diet allowing a more focused and actionable result for practitioners and their patients.

 

The Board expects installation at the laboratory to commence later this month and after a period of validation and gaining necessary approvals, the processing of tests to begin later this quarter. As well as being CLIA certified, the laboratory receiving the system is also College of American Pathologists accredited and specialises in providing functional tests for both consumers and healthcare practitioners.

 

Omega has also secured an importer for FoodPrint® kits into the USA. The importer will import kits for the CLIA laboratory as well as for Omega's own direct channels in future.

 

Although the value of this initial PO is circa £50,000, the US market is a key area of focus for Omega's growth strategy and this installation will be the first in the US market in over seven years, representing the beginning of Omega's planned expansion into the USA.

 

Jag Grewal, CEO of Omega Diagnostics, said: "The US is the single largest market for food sensitivity testing globally, with an ever-increasing demand for personalised medicine, and is a focus area for our growth plans. This installation reflects a key milestone in our expansion plans, the receiving laboratory is ideally placed to commercialise FoodPrint® in the US market as they are already providing a range of other functional tests. The appointment of the US importer will act as a foundation for our expansion into the region.

 

"Once the system has been commissioned, we plan to collaborate closely with our laboratory partner to ensure FoodPrint® is promoted effectively through their existing healthcare practitioner and direct to consumer channels."

 

 

Contacts: 

Omega Diagnostics Group PLC 

www.omegadx.com

Jag Grewal, Chief Executive Officer 

via Walbrook PR

Chris Lea, Chief Financial Officer

finnCap Ltd  

Tel: 020 7220 0500

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/Charlotte Sutcliffe (ECM)

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Applegarth

Mob: 07584 391 303

Sam Allen

Mob: 07502 558 258

 

About Omega Diagnostics Group PLC

Omega (AIM: ODX) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

www.omegadx.com

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBAMLTMTTMBAJ
Date   Source Headline
10th Apr 20187:00 amRNSStrategic Review of operations and Trading Update
12th Jan 201812:14 pmRNSHolding(s) in Company
21st Dec 20177:00 amRNSAllersys® CE-Mark
14th Dec 20177:01 amRNSCEO succession
14th Dec 20177:00 amRNSInterim results
29th Nov 20177:00 amRNSVISITECT® CD4 CE-Mark
1st Nov 20177:00 amRNSChange of Registered Office
23rd Oct 20177:00 amRNSTrading Update and Notice of Interim Results
18th Oct 20179:00 amRNSPDMR Participation in SAYE Scheme
16th Oct 20177:00 amRNSUS Supply Agreement
10th Oct 20177:00 amRNSHolding(s) in Company
5th Sep 20172:07 pmRNSExercise of Options and Total Voting Rights
29th Aug 201711:51 amRNSResult of AGM
18th Jul 201710:35 amRNSResult of General Meeting
6th Jul 201711:56 amRNSSale and leaseback of building owned by Omega GmbH
30th Jun 201712:13 pmRNSResult of Proposed Fundraising
30th Jun 20177:01 amRNSProposed Fundraising
30th Jun 20177:00 amRNSFinal Results
25th Apr 20177:00 amRNSTrading Update and Notice of Results
21st Apr 201712:41 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSVISITECT® Malaria CE-Mark & Indian FDA inspection
7th Mar 20178:45 amRNSHolding(s) in Company
27th Feb 201712:52 pmRNSHolding(s) in Company
27th Jan 20177:00 amRNSUpdate on discussions with IDS
11th Jan 20177:00 amRNSISO accreditation for manufacturing facility
29th Nov 20167:15 amRNSHardman Research: Food intolerance driving growth
24th Nov 20167:52 amRNSHolding(s) in Company
21st Nov 20167:00 amRNSHalf-year Report
31st Oct 20167:15 amRNSHardman Research: Diagnosing growth opportunities
17th Oct 20167:00 amRNSTrading Update and Notice of Interim Results
10th Aug 201612:22 pmRNSResult of AGM
2nd Aug 20167:00 amRNSR&D Grant Funding
4th Jul 20168:18 amRNSHolding(s) in Company
1st Jul 201611:48 amRNSHolding(s) in Company
27th Jun 20167:00 amRNSFinal Results
9th Jun 20169:07 amRNSHolding(s) in Company
21st Apr 20167:00 amRNSTrading Update & Notice of Results
8th Feb 20168:22 amRNSHolding(s) in Company
4th Dec 20154:25 pmRNSHolding(s) in Company
3rd Dec 201512:28 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSHalf Yearly Report
26th Oct 20157:00 amRNSTrading Update and Notice of Interim Results
30th Sep 20159:07 amRNSGrant of Options
7th Sep 20151:21 pmRNSResult of AGM
7th Jul 20157:00 amRNSFinal Results
5th Jun 201510:01 amRNSHolding(s) in Company
1st Jun 20157:00 amRNSDevelopment Update - Visitect® CD4 and Allergy
27th Apr 20157:00 amRNSBoard Appointment
15th Apr 20157:00 amRNSTrading update and Notice of Results
1st Dec 201410:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.